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Abstract
Background: Sequencing data from The Cancer Genome Atlas (TGCA), the International Cancer Genome
Consortium and other research institutes have revealed the presence of genetic alterations in several tumor
types, including gastric cancer. These data have been combined into a catalog of significantly mutated genes
for each cancer type. However, it is unclear to what extent significantly mutated genes need to be examined
for detecting genetic alterations in gastric cancer patients. Here, we constructed two custom-made sequencing
panels of different scales, the Selective hotspot Panel and the Comprehensive Panel, to analyze genetic
alterations in 21 resected specimens endoscopically obtained from 20 gastric cancer patients, and we assessed
how many mutations were detectable using these different panels.
Results: A total of 21 somatic mutations were identified by the Selective hotspot Panel and 70 mutations
were detected by the Comprehensive Panel. All mutations identified by the Selective hotspot Panel were
detected by the Comprehensive Panel, with high concordant values of the variant allelic fraction of each
mutation (correlation coefficient, R = 0.92). At least one mutation was identified in 13 patients (65 %) by the
Selective hotspot Panel, whereas the Comprehensive Panel detected mutations in 19 (95 %) patients. Library
preparation and sequencing costs were comparable between the two panels.
Conclusions: Our results indicate the utility of comprehensive panel-based targeted sequencing in gastric cancer.
Keywords: Endoscopic submucosal dissection, Endoscopy, Gastric cancer, Ion PGM, Ion Proton, Mutation,
Next-generation sequencing, Targeted sequencing, Tumor
Background
Gastric cancer is the third- and fifth-highest cause of
cancer mortality in men and women, respectively, and
accounts for 8 % of total cancer cases and 10 % of
total cancer-related deaths worldwide [1]. The highest
incidence rates of gastric cancer are in Eastern Asia,
Eastern Europe, and South America, while the lowest
rates are in North America and most parts of Africa
[1]. Major risk factors include Helicobacter pylori and
Epstein–Barr virus infection, as well as dietary factors
such as excessive salt intake [2, 3].
Gastric cancer develops in a step-wise manner, involving
chronic gastritis, atrophy, intestinal metaplasia, and
dysplasia [4]. Early gastric cancer presents as a malignant
tumor confined to the mucosa or submucosa, regardless
of the presence of regional lymph node metastasis [5, 6].
The detection of early gastric cancer has recently
improved, following the development of endoscopic
techniques [7, 8]. In particular, endoscopic submucosal
dissection (ESD) has enabled a high en bloc resection
rate for small and large lesions, as well as in patients
with scarring. Moreover, the specimens obtained by
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ESD can be used for a histological assessment of curability
[9]. Endoscopic resection is now widely accepted as a low
invasive method for the local resection of early gastric
cancer with a negligible risk of lymph node metastasis
[10, 11]. Endoscopically-resected early gastric cancer
also provides suitable material for genomic analysis to
better understand the molecular and genetic features
of the initial event leading to cancer development [12].
Next-generation sequencing (NGS) technology enables
us to determine the sequence of the genome at a range
of different scales, including whole genome, whole
exome, and the targeted sequencing of multiple regions
of interest. Whereas large-scale analyses are essential for
discovery projects, targeted sequencing can focus on
genes associated with disease and may lead to advances
in the molecular diagnostics of cancer [13]. As an
example, NGS has identified a subset of driver and
tumor suppressor genes associated with several cancer
types [14]. It can also produce thousands to millions of
short sequence reads that are massively parallel, and
offers a cost-effective approach for detecting genetic
alterations.
Large amounts of sequencing data have been disclosed
from The Cancer Genome Atlas (TCGA), the Inter-
national Cancer Genome Consortium (ICGC) and other
research institutes. Analyses of these data identified
significantly mutated genes (SMGs) in several cancer
types [15, 16]. Although SMGs have been revealed by
whole exome and whole genome sequencing data, it is
unclear to what extent SMGs need to be examined for
detecting genetic alterations in gastric cancer. In the
present study, we used gastric cancer-associated SMGs
to construct two sequencing panels of different scales
[17–23]. We performed targeted sequencing and ana-
lyzed genetic alterations in gastric tumors at an early
phase and assessed how many mutations were detectable
using these different panels.
Methods
Patients and sample preparation
This study included 20 patients who were diagnosed
with gastric cancer (16 males and four females; age
60–87 years) at our hospital (Yamanashi, Japan), one of
whom had two tumors. Informed consent was obtained
from all subjects. This study was approved by the Institu-
tional Review Board at our hospital and complied with
Declaration of Helsinki principles. Peripheral blood
samples were obtained from gastric cancer patients and
DNA extraction was performed as previously described
[24]. Briefly, peripheral blood samples were centrifuged at
820 × g at 25 °C for 10 min, and buffy coats were isolated
and stored at −80 °C until required for DNA extraction.
Buffy coat DNA was extracted using the QIAamp DNA
Blood Mini QIAcube Kit (Qiagen, Hilden, Germany) with
the QIAcube (Qiagen). The concentration of DNA was
determined using the Nano Drop 2000 spectrophotometer
(Thermo Fisher Scientific, Waltham, MA).
Laser capture microdissection and histology
Tumor samples were fixed using 10 % buffered formalin.
Serial sections of 10-μm-thick, formalin-fixed, paraffin-
embedded (FFPE) tissue were stained with hematoxylin
and eosin, and then microdissected using an ArcturusXT
laser capture microdissection system (Thermo Fisher
Scientific) using ESD-resected specimens. Tumor cells
from endoscopic biopsy samples were obtained from 25
serial sections because of the high tumor content.
Tumor DNA was extracted using the QIAamp DNA
FFPE Tissue Kit (Qiagen).
DNA quality analysis
The integrity of purified DNA from FFPE samples was
assessed using the TaqMan RNase P Detection Reagents
kit and the FFPE DNA QC Assay v2 on the ViiA 7
Real-Time PCR System (Thermo Fisher Scientific).
Human control genomic DNA included in the TaqMan
RNase P Detection Reagents Kit was diluted to create a
five-point serial dilution for a standard curve, and abso-
lute DNA concentrations were determined. DNA frag-
mentation was estimated as the ratio of DNA (relative
quantification; RQ) obtained for the long amplicon to
the short amplicon. High RQ values indicated that
the genomic DNA was intact and high quality.
Selecting genes and primer design
We searched the literature and selected genes based
on the following criteria (Additional file 1: Table S1):
(a) SMGs relative to the background mutation rates
analyzed by MutSigCV analysis tool [17]; (b) genes
involved in signaling pathways and potential therapeutic
targets in gastric cancer; and (c) known drivers of gastric
carcinogenesis reported by TCGA [17] and other projects
[18–22]. We examined the hotspot mutation site of each
gene in gastric cancer from the COSMIC database (http://
cancer.sanger.ac.uk/cancergenome/projects/cosmic).
We selected 20 genes for the Selective hotspot Panel,
which comprises a subset of SMGs and genes related to
receptor tyrosine kinases (RTKs) and RAS signaling path-
way based on the TCGA project [17]. To expand and
cover more SMGs, we selected 58 genes (which include
the 20 genes in the Selective hotspot Panel) based on pub-
lished data from TCGA and another research institute
[17–23]. Ion AmpliSeq designer software (Thermo Fisher
Scientific) was used to design two custom sequencing
panels: the Selective hotspot Panel targeting 20 genes in
gastric cancer and the Comprehensive Panel targeting 58
genes [17–23] (Table 1). A total of 376 and 3515 pri-
mer pairs were contained within the Selective hotspot
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Panel (covering 38.01 kb) and the Comprehensive
Panel (covering 351.05 kb), respectively.
Targeted sequencing
Targeted sequencing was performed as previously de-
scribed [25]. Multiplex polymerase chain reaction (PCR)
of these panels was performed using the Ion AmpliSeq
Library Kit 2.0 (Thermo Fisher Scientific). Primer
sequences were digested with FuPa reagent (Thermo
Fisher Scientific), and then barcoded using Ion Xpress
Barcode Adapters (Thermo Fisher Scientific). Purifica-
tion was carried out by Agencourt AMPure XP reagents
(Beckman Coulter, Brea, CA). The library concentration
was determined using an Ion Library Quantitation Kit
(Thermo Fisher Scientific); each library was diluted to
10 pM, and the same amount of libraries was pooled for
one sequence reaction. Emulsion PCR was carried out
using the Ion OneTouch System and Ion PGM Template
OT2 200 kit or Ion PI Template OT2 200 Kit v3
(Thermo Fisher Scientific). Template-positive Ion Sphere
Particles were then enriched using the Ion OneTouch ES
system (Thermo Fisher Scientific), and purified Ion
Sphere particles were loaded on an Ion 318 Chip v2 or
PI Chip (Thermo Fisher Scientific). Massively parallel
sequencing was carried out on Ion PGM or Ion Proton
systems (Thermo Fisher Scientific).
Data analysis
Sequence data were processed using standard Ion
Torrent Suite Software running on the Torrent Server.
Raw signal data were analyzed using Torrent Suite version
4.4. The data processing pipeline involved signaling
processing, base calling, quality score assignment, adapter
trimming, PCR duplicate removal, read alignment to the
human genome 19 reference (hg19), quality control of
mapping quality, coverage analysis, and variant calling.
Following data analysis, the annotation of single nucleo-
tide variants, insertions, and deletions was performed by
the Ion Reporter Server System (Thermo Fisher Scien-
tific), and peripheral blood DNA was used as a control to
detect variants in tumors (Tumor–Normal pairs). We
used the following filtering parameters for variant calling:
the minimum number of variant allele reads was ≥5, the
coverage depth was ≥10, and the variant allele fraction
was ≥10 %. If somatic mutations were called using either
the Selective hotspot Panel or Comprehensive Panel, se-
quence data were visually confirmed with the Integrative
Genomics Viewer and any sequence, alignment, or variant
call error artifacts were discarded.
Results
Quality assessment of extracted FFPE DNA
We examined 21 FFPE tumor samples collected from
20 patients (early stage, 19 patients; advanced stage, one
patient) who had not previously undergone chemotherapy
or radiotherapy. Matched peripheral blood lymphocytes
were included as a control. Of the 21 FFPE tumor
samples, 19 tumors had been resected by ESD and
two by endoscopic biopsy. ESD-resected tumor tissue
was dissected by laser capture microdissection with an
average cutting area of 29.4 mm2 (range, 12.4–51.5 mm2)










Selective hotspot Panel 38.01 kb 376 20 99.99 % APC*, ARID1A, BCOR, CDH1*, CTNNB1*, EGFR*, ERBB2*, ERBB3, FGFR2*, JAK2*,
KRAS*, MET*, NRAS*, PIK3CA*, PTEN*, RASA1, RHOA*, RNF43, SMAD4*, TP53*
Comprehensive Panel 351.05 kb 3515 58 96.86 % ABCA10, ACVR2A, AKAP13, APC, ARHGAP5, ARID1A, BCOR, BNC2, CD274,
CDH1, CNGA4, CTNNA1, CTNNA2, CTNNB1*, DLC1, DNAH7, EGFR, EIF2C4,
ELF3, ERBB2, ERBB3, EYA4, FAM46D, FAT4, FGFR1, FGFR2, GLI3, JAK2,
KIF2B, KMT2A, KMT2C, KRAS*, LDOC1, MACF1, MET, MUC6, NRAS*, PCDH9,
PDCD1LG2, PIK3CA, PIK3R1, PKHD1, PLB1, PTEN, PTPRC, RASA1, RGNEF,
RHOA*, RNF43, SMAD2, SMAD4, SOHLH2, SYNE1, TGFBR2, TMPRSS2,
TP53, VEGFA, ZIC4
Genes shown in bold font represent the 20 identified by the Selective hotspot Panel
*Genes targeting hotspot regions
Pre-LCM Post-LCM
Fig. 1 Representative image of microdissected specimen. Tumor cells were obtained from ESD-resected specimens using laser capture microdissection
(LCM). Left image (Pre-LCM) is before microdissection; right image is after microdissection (Post-LCM). Cyan circles indicate the cutting area
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Table 2 Coverage depth of the data from the two panels
Selective hotspot Panel Comprehensive Cancer Panel
Case Sample Mapped Reads On Target Mean Depth Uniformity Mapped Reads On Target Mean Depth Uniformity
Case 1 Buffy coat 484124 98.0 % 1402 94.0 % 1097404 96.4 % 307 96.0 %
Case 2 Buffy coat 426768 98.1 % 1233 94.0 % 1267404 96.3 % 355 96.1 %
Case 3 Buffy coat 518868 98.2 % 1507 93.8 % 810553 96.3 % 221 95.0 %
Case 4 Buffy coat 542769 98.4 % 1576 93.9 % 379011 96.1 % 106 94.5 %
Case 5 Buffy coat 624920 97.9 % 1796 94.3 % 11170406 96.8 % 3112 95.1 %
Case 6 Buffy coat 164634 98.9 % 477 93.5 % 2069779 97.9 % 611 90.6 %
Case 7 Buffy coat 126183 99.0 % 363 91.0 % 2256973 97.8 % 666 91.0 %
Case 8 Buffy coat 108641 99.1 % 315 90.5 % 2027465 97.7 % 601 92.0 %
Case 9 Buffy coat 166684 99.0 % 487 94.7 % 1857285 97.8 % 551 92.2 %
Case 10 Buffy coat 107898 99.0 % 314 90.7 % 2013379 98.0 % 593 89.0 %
Case 11 Buffy coat 79551 99.2 % 231 87.1 % 2106246 98.1 % 624 88.7 %
Case 12 Buffy coat 67486 99.2 % 197 88.3 % 1859173 98.3 % 542 82.5 %
Case 13 Buffy coat 60485 99.2 % 175 91.2 % 1918204 98.3 % 548 78.6 %
Case 14 Buffy coat 260250 98.8 % 759 92.4 % 1295372 96.7 % 360 94.9 %
Case 15 Buffy coat 235410 98.7 % 680 94.2 % 1053705 96.9 % 293 94.6 %
Case 16 Buffy coat 246227 99.0 % 715 93.7 % 845571 97.0 % 234 94.7 %
Case 17 Buffy coat 268465 98.8 % 779 94.4 % 1223358 96.8 % 341 95.2 %
Case 18 Buffy coat 280097 99.1 % 811 93.9 % 3130126 97.0 % 902 93.6 %
Case 19 Buffy coat 256281 98.9 % 744 94.5 % 3423132 97.0 % 987 94.4 %
Case 20 Buffy coat 207402 98.9 % 598 92.4 % 2913580 97.0 % 830 93.6 %
Mean ± SD 261657 ± 170658 98.7 ± 0.42 % 758 ± 493 92.6 ± 2.1 % 2235906 ± 2247475 97.2 ± 0.71 % 639 ± 627 92.1 ± 4.6 %
Case 1 Tumor 403252 98.5 % 1143 87.8 % 2025838 97.7 % 522 71.0 %
Case 2 Tumor 426999 98.4 % 1222 91.6 % 999656 96.9 % 276 94.1 %
Case 3 Tumor 524706 98.5 % 1502 91.8 % 1032722 96.3 % 281 94.6 %
Case 4 Tumor 467625 98.0 % 1337 91.0 % 789820 95.8 % 210 95.2 %
Case 5 Tumor 412941 98.5 % 1186 90.7 % 829933 96.0 % 223 94.9 %
Case 6 Tumor 72752 99.3 % 207 84.8 % 1949114 98.6 % 577 83.2 %
Case 7 Tumor 119809 99.3 % 340 85.8 % 2511041 97.6 % 718 91.2 %
Case 8 Tumor 85768 99.2 % 246 88.2 % 1521154 98.6 % 437 82.4 %
Case 9 Tumor 182739 99.2 % 523 89.0 % 2048473 98.2 % 583 88.3 %
Case 10 Tumor 110281 98.0 % 311 88.5 % 2702014 97.3 % 762 87.2 %
Case 11 Tumor 96338 99.2 % 273 89.8 % 2668972 98.0 % 750 86.1 %
Case 12 Tumor 106265 99.2 % 303 87.7 % 2382665 97.8 % 673 89.0 %
Case 13 Tumor site1 87099 98.8 % 250 92.4 % 2861114 97.5 % 819 91.1 %
Case 13 Tumor site2 138279 99.3 % 395 88.9 % 2705723 97.9 % 777 91.5 %
Case 14 Tumor 230616 98.9 % 662 92.6 % 781688 96.5 % 211 95.1 %
Case 15 Tumor 262428 99.1 % 742 65.8 % 631147 96.6 % 171 95.2 %
Case 16 Tumor 179627 99.1 % 512 87.8 % 3189103 95.9 % 929 95.8 %
Case 17 Tumor 153577 99.0 % 434 85.7 % 539462 96.5 % 145 95.0 %
Case 18 Tumor 145284 98.4 % 411 94.7 % 2514172 96.4 % 697 91.0 %
Case 19 Tumor 184785 97.6 % 520 94.0 % 2333968 95.0 % 637 91.4 %
Case 20 Tumor 105210 97.8 % 294 95.0 % 1663278 96.6 % 436 80.3 %
Mean ± SD 214113 ± 143314 98.7 ± 0.54 % 610 ± 411 88.7 ± 6.0 % 1841955 ± 850360 97.0 ± 1.0 % 516 ± 247 89.7 ± 6.3 %
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(Fig. 1 and Additional file 1: Table S2). Endoscopic biopsy
samples were not microdissected because of the high
tumor content.
To assess the extent of DNA degradation, we performed
quantitative real-time PCR using two primer pairs
(short amplicon, 87 bp; long amplicon, 268 bp) flanking
the human RNase P locus [26, 27]. Short and long DNA
fragment yields were estimated as 14.4 ng/μL (range,
0.6–65.0 ng/μL) and 8.0 ng/μL (range, 0.2–35.8 ng/μL),
respectively (Additional file 1: Table S3). An estimate
of FFPE-derived genomic DNA fragmentation using the
RQ gave an average value of 0.49 (range, 0.14–0.73)
(Additional file 1: Table S3), indicating that DNA of high
quality had been extracted from FFPE specimens.
Targeted sequencing analysis
To identify genetic alternations in gastric cancer, we
reviewed cancer genome sequences from TCGA, ICGC,
and COSMIC databases, and selected all SMGs asso-
ciated with gastric cancer. We constructed two custom-
made gastric cancer panels. The Selective hotspot Panel
spans 38,010 nucleotides, covers 20 SMGs, and mainly
targets hotspot regions (Table 1). The Comprehensive
Panel spans 354,050 nucleotides, and 58 of the genes
contained within this panel overlapped with the Select-
ive hotspot Panel (Table 1).
We performed targeted sequencing using the two
panels with a next-generation sequencer (Ion Proton or
Ion PGM, Thermo Fisher Scientific). The percentage of
mapped reads aligned to target regions was 98.7 %
(97.6–99.3 %) in the Selective hotspot Panel and
97.0 % (95.0–98.6 %) in the Comprehensive Panel,
suggesting that all FFPE-derived DNAs had been suc-
cessfully subjected to library preparation following se-
quencing analysis (Table 2).
The mean coverage depth of tumors was 610×
(range, 207–1502) by the Selective hotspot Panel, and
516× (range, 145–923) by the Comprehensive Panel
(Table 2). The two approaches identified a total of 21 and
70 somatic mutations in tumors, respectively (Fig. 2a and
Table 3). All 21 mutations identified by the Selective hot-
spot Panel were also confirmed by the Comprehensive
Panel (Fig. 2a). The variant allelic fraction values were sig-
nificantly correlated between the two panels (Fig. 2b).
Seventy mutations were detected in the 21 tumors.
Overall, an average of 3.2 mutations (range, 0–8) were
detected in each early gastric tumor, whereas seven mu-
tations were detected in the advanced tumor. At least
one mutation was detected in 13 of the 20 patients
(65 %) by the Selective hotspot Panel, and in 19 of the 20
patients (95 %) by the Comprehensive Panel. These re-
sults suggest that the Comprehensive Panel covered the
genetic alterations of almost all gastric cancer patients.
Running costs
Primer costs for the Comprehensive Panel were higher
than those of the Selective hotspot Panel (Comprehen-
sive Panel: $26363 vs. Selective hotspot Panel: $2820).
However, the total cost of library preparation, emersion
PCR, and massively parallel sequencing was comparable
between the two panels at $200–250 per sample. Use of
the Barcode Xpress toolkit enabled multiple samples to
be simultaneously sequenced in 4–5 h and allowed us to
obtain high-depth sequence data using the Ion PGM or
Ion Proton system.
Discussion
The identification of oncogenic driver genes has led to
the development of potent molecular targeting drugs
together with companion diagnostics. The advent of
NGS has also resulted in the identification of a subset of
cancer-related genes in several tumors [14, 15], inclu-
ding hundreds of genes mainly associated with tumor
development [28]. TCGA, ICGC, and other research
institutes have revealed a tumor mutational landscape
and produced a catalog of somatic mutations associated
with tumors. Information from this catalog has enabled
the analysis of recurrently mutated genes by targeted
sequencing [29]. This is a useful, cost-effective method
for identifying variants in dozens to hundreds of genes,
and is fairly readily available for routine diagnosis in a
clinical setting as well as for research purposes.
In this study, we constructed two amplicon-based
targeted panels of different scales to analyze the genetic
alterations associated with gastric cancer. In our cohort,
20 out of 21 tumors (95 %) were shown to carry at least
one mutation by the Comprehensive Panel. Thus, our
panel-based approach enabled us to detect somatic
mutations in gastric cancer, suggesting that it has the




































Fig. 2 Correlation of variant allele fractions detected in the two panels.
Panel a: Venn diagram of identified mutations in the two panels.
Twenty-one variants identified by the Selective hotspot Panel
were also detected by the Comprehensive Panel. Panel b: Compari-
son of variant allelic fractions (AF) between the two panels. The AF
value of 21 variants is plotted. The correlation coefficient (R) is 0.92
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Table 3 Somatic mutations identified using the two panels




Case 1 ESD Early MUC6 F1843S Not included 28 %
MUC6 S1531P Not included 23 %
PKHD1 F83S Not included 11 %
Case 2 ESD Early ZIC4 R107H Not included 21 %
RASA1 K825X Not included 21 %
Case 3 ESD Early MACF1 L2900F Not included 11 %
Case 4 ESD Early APC C207X Not included 34 %
APC Q1447X 35 % 31 %
MUC6 A1637Q Not included 16 %
SYNE1 D5070G Not included 13 %
PKHD1 Q3467K Not included 12 %
MUC6 L1836H Not included 10 %
Case 5 ESD Early SYNE1 G474R Not included 83 %
TP53 G266V 83 % 65 %
PKHD1 R723C Not included 32 %
FAM46D S69C Not included 16 %
Case 6 ESD Early MUC6 T2041M Not included 33 %
SMAD2 A278P Not included 17 %
MACF1 R3680K Not included 14 %
Case 7 ESD Early TP53 D148fs 67 % 61 %
Case 8 ESD Early APC L1564X 42 % 59 %
SYNE1 D903Y Not included 43 %
APC S940X Not included 42 %
TMPRSS2 L141V Not included 40 %
AKAP13 A2256V Not included 28 %
MUC6 T2041M Not included 25 %
MUC6 P1571T Not included 21 %
Case 9 ESD Early APC Q1237fs Not included 38 %
Case 10 ESD Early TP53 H193Y 63 % 52 %
APC S1068X Not included 42 %
SMAD4 G477X Not included 35 %
KRAS G13D 38 % 33 %
RHOA M1V 13 % 14 %
APC Q1517fs 5 % 14 %
Case 11 ESD Early ELF3 D220N Not included 42 %
SYNE1 K874N Not included 40 %
SMAD4 R497H 28 % 39 %
FAT4 K225E Not included 35 %
KMT2C Y987H Not included 33 %
ERBB2 R897Q Not included 32 %
SYNE1 R7753H Not included 32 %
MET N381fs 19 % 13 %
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events in tumors. Furthermore, two patients (10 %)
harbored mutations in potential therapeutic targets such
as KRAS (5 %), ERBB2 (5 %) and MET (5 %) [17, 23].
With the increasing numbers of molecular targeting
drugs under development or clinical trial, Comprehen-
sive Panels may offer better selection for molecular-
targeted therapy for gastric cancer patients. Collectively,
this demonstrates the utility of targeted sequencing
using a multi-gene panel in cancer genome research
and clinical settings.
Progress in endoscopic technology has led to the
curative resection of gastric cancer at an early stage.
However, although ESD is widely performed to resect
early gastric cancer, the genetic alterations occurring in
such tumors are not fully understood, even though this
would provide us with an insight into the mechanisms
of tumorigenesis. Here, we performed targeted sequencing
using ESD-resected early gastric cancers, together with
endoscopically-resected biopsies of advanced cancer. A
total of 70 somatic mutations were identified in 19
patients, and an average 3.2 mutations were found in early
gastric cancer. The most recurrent mutation was identi-
fied in TP53 gene (43 %, 9/21). In line with this observa-
tion, previous studies have shown that TP53 mutations
occur in early gastric cancer as well as in high-grade
intraepithelial neoplasia [30]. These observations indicate
that TP53 is a key molecule for the progression of
gastric tumorigenesis.
In this study, somatic mutations in TP53 (43 %), APC
(29 %), MUC6 (33 %), and SYNE1 (24 %) were frequently
observed (identified in over 20 % of tumors). These
frequencies are almost consistent with previous studies
Table 3 Somatic mutations identified using the two panels (Continued)
Case 12 ESD Early APC R876X 38 % 38 %
MUC6 T2041M Not included 28 %
Case 13_site1a ESD Early TP53 R209fs 70 % 67 %
ARHGAP5 L297X Not included 31 %
PKHD1 I3786M Not included 12 %
Case 13_site2a ESD Early TP53 E258D Not included 71 %
MACF1 D968A Not included 51 %
Case 14 ESD Early - - Not detected Not detected
Case 15 ESD Early SYNE1 R6836C Not included 51 %
ACVR2A R202fs Not included 39 %
MUC6 S2378fs Not included 38 %
DLC1 E854K Not included 17 %
Case 16 ESD Early ARID1A K1072fs 43 % 51 %
RASA1 R512X 44 % 41 %
TP53 G154S 35 % 32 %
RASA1 D380E 18 % 19 %
MUC6 P1724S Not included 15 %
ARHGAP5 L259S Not included 10 %
Case 17 ESD Early CTNNB1 S45F 40 % 32 %
Case 18 ESD Early TP53 N200fs 3 % 16 %
Case 19 Biopsy Early TP53 R175H 15 % 6 %
APC E262X Not included 12 %
Case 20 Biopsy Advanced TGFBR2 S94R Not included 28 %
CDH1 Splice site Not included 28 %
MACF1 G5253E Not included 19 %
TP53 R248Q 17 % 16 %
DNAH7 Y2563N Not included 13 %
DLC1 W10L Not included 13 %
CDH1 Splice site (c.1009-2A>C) 13 % 8 %
aCase 13 had two tumors
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that reported mutations in TP53 (36–73 %), APC
(5–14 %), MUC6 (6–18 %), and SYNE1 (20 %). Less
common mutations were observed in CTNNB1 (5 %) and
KRAS (5 %) genes in our study, but these gene mutations
(CTNNB1 S45F and KRAS G13D) are well-known hotspot
driver mutations [31]. Previous data also showed that
CTNNB1 (1–9 %) and KRAS (5–6 %) mutations were
relatively uncommon in gastric cancer. These results
indicated that our designed panels validated the data
of previous reports.
The TCGA project demonstrated there are four major
subtypes of gastric cancer based on the genomic ana-
lysis, i.e., chromosomal instability (CIN), genomically
stable (GS), Epstein-Barr virus-positive and microsa-
tellite instability [17]. According to this molecular
classification, TP53 mutation mostly occurs in the CIN
category and intestinal histology. Consistent with this,
we examined ESD-resected gastric tumors and most
were intestinal type gastric cancer (data not shown).
Additionally, the GS subtype is classified as diffuse
histology and frequently shows CDH1 and RHOA muta-
tions and CLDN18-ARHGAP fusion. Again, in our series,
one advanced gastric cancer was diffused type histology
and had a CDH1 splice site mutation (Case 20 in Table 3).
Collectively, our data reinforced the molecular classi-
fications of gastric cancer.
Analyses that include a large number of SMGs are
important for several reasons. First, analyzing additional
SMGs will detect more somatic alterations in tumors.
In this study, we were unable to identify any mutations in
seven patients using the Selective hotspot Panel, com-
pared with only one using the Comprehensive Panel
(Table 3). A recent study reported newly identified SMGs
including NRG1, ERBB4, XIRP2, NBEA, COL14A1,
CNBD1, ITGAV, and AKAP6 [32, 33] that should be
included in the mutational spectrum analyzed in all pa-
tients with gastric cancer. Second, from a cost perspective,
covering more SMGs is beneficial, as shown by the com-
parable library preparation and sequencing running costs
between the two panels used in this study. Third, includ-
ing more primer pairs in the design of the panel en-
ables more high-resolution copy number data to be
examined [34]. Previous bioinformatics analysis combined
with variant allelic fraction and copy number alteration
data revealed the cellular prevalence of tumor heterogen-
eity [35]. Together, these findings suggest that SMG-based
sequencing analysis is a useful method for further investi-
gating tumor heterogeneity in clinical samples.
Conclusions
In the present study, use of the Comprehensive Panel
covering SMGs associated with gastric cancer enabled
the analysis of genetic alterations in patients with early
gastric cancer.
Additional file
Additional file 1: Table S1. Panel description and references. Table S2.
Cutting areas of ESD-resected specimens (n=19) by laser capture
microdissection and biopsies (n=2). Table S3. Assessment of
tumor-derived DNA qualities. (XLS 43 kb)
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